<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737996</url>
  </required_header>
  <id_info>
    <org_study_id>1241.35</org_study_id>
    <secondary_id>2012-003697-10</secondary_id>
    <nct_id>NCT01737996</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects</brief_title>
  <official_title>An Open-label, Multiple Dose Study to Assess Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID Administered Orally for 9 Days (Part 1) and Multiple Doses of BI 207127 Combined With Faldaprevir Administered Orally for 16 Days (Part 2) in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current trial is to evaluate safety, tolerability and pharmacokinetics
      of different multiple doses of BI 207127 BID and multiple doses of BI 207127 combined with
      faldaprevir in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Healthy Subjects With AEs (Multiple Rising Dose Part)</measure>
    <time_frame>From first drug administration (Day 1) until end of trial examination (15 to 21 days after first administration)</time_frame>
    <description>Number of healthy subjects with any adverse event (AE) during the on-treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 hours (h) after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve (AUC) of Deleobuvir over the uniform dosing interval 0 to 12 h (hours) on Day 1 and at steady state on Day 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and Cmax,ss of Deleobuvir (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(12h) and C(12h,ss) of Deleobuvir (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Concentration of Deleobuvir at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and Cmax,ss of CD 6168 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(12h) and C(12h,ss) of CD 6168 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Concentration of CD 6168 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and Cmax,ss of BI 208333 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(12h) and C(12h,ss) of BI 208333 (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Concentration of BI 208333 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(12h) and C(12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Concentration of CD 6168 acylglucuronide at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24h) and AUC(0-24h,ss) of Faldaprevir (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of Faldaprevir over the uniform dosing interval 0 to 24 h on Day 1 and at steady state on Day 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax and Cmax,ss of Faldaprevir (Combined Treatment Part)</measure>
    <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12, 24 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of Faldaprevir on Day 1 and at steady state on Day 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of Deleobuvir over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Cmax,ss of Deleobuvir (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Cmax,ss of CD 6168 (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Cmax,ss of BI 208333 (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</measure>
    <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
    <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 + faldaprevir</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male and female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.35.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <results_first_submitted>January 21, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2016</results_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The 600mg dose cohort was to be started at least 6 days after the 400mg dose cohort was completed and the combined treatment cohort (600mg Deleobuvir + 120mg Faldaprevir) was started after the evaluation of key safety and tolerability data of the individual treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>400 mg Deleobuvir</title>
          <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose (MRD) part.</description>
        </group>
        <group group_id="P2">
          <title>600 mg Deleobuvir</title>
          <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose (MRD) part.</description>
        </group>
        <group group_id="P3">
          <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
          <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14">One patient withdrew consent after the first dose due to private reasons.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study comprised 2 trial parts: a multiple rising dose part (Part 1) followed by a combined treatment part (Part 2). The multiple rising dose part was performed in an open-label, non-randomised, non-placebocontrolled manner with 2 dose groups. The combined treatment part was conducted open-label in 1 treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>400 mg Deleobuvir</title>
          <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
        </group>
        <group group_id="B2">
          <title>600 mg Deleobuvir</title>
          <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
        </group>
        <group group_id="B3">
          <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
          <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="10.4"/>
                    <measurement group_id="B2" value="37.3" spread="5.1"/>
                    <measurement group_id="B3" value="38.3" spread="10.6"/>
                    <measurement group_id="B4" value="38.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Multiple Rising Dose Part)</title>
        <description>Area under the concentration-time curve of Deleobuvir over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Multiple Rising Dose Part)</title>
          <description>Area under the concentration-time curve of Deleobuvir over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8210" spread="45.5"/>
                    <measurement group_id="O2" value="18000" spread="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6160" spread="45.2"/>
                    <measurement group_id="O2" value="18500" spread="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Healthy Subjects With AEs (Multiple Rising Dose Part)</title>
        <description>Number of healthy subjects with any adverse event (AE) during the on-treatment period.</description>
        <time_frame>From first drug administration (Day 1) until end of trial examination (15 to 21 days after first administration)</time_frame>
        <population>Treated Set. The treated set included all subjects who were documented to have taken at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Healthy Subjects With AEs (Multiple Rising Dose Part)</title>
          <description>Number of healthy subjects with any adverse event (AE) during the on-treatment period.</description>
          <population>Treated Set. The treated set included all subjects who were documented to have taken at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Combined Treatment Part)</title>
        <description>Area under the concentration-time curve (AUC) of Deleobuvir over the uniform dosing interval 0 to 12 h (hours) on Day 1 and at steady state on Day 16.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 hours (h) after drug administration in the morning.</time_frame>
        <population>PKS. The pharmacokinetic set (PKS) included all subjects of the treated set who provided at least 1 observation for at least 1 pharmacokinetic endpoint without important protocol violations relevant for the statistical evaluation of pharmacokinetic endpoints. Including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of Deleobuvir (Combined Treatment Part)</title>
          <description>Area under the concentration-time curve (AUC) of Deleobuvir over the uniform dosing interval 0 to 12 h (hours) on Day 1 and at steady state on Day 16.</description>
          <population>PKS. The pharmacokinetic set (PKS) included all subjects of the treated set who provided at least 1 observation for at least 1 pharmacokinetic endpoint without important protocol violations relevant for the statistical evaluation of pharmacokinetic endpoints. Including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37500" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51400" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax and Cmax,ss of Deleobuvir (Combined Treatment Part)</title>
        <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 16.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of Deleobuvir (Combined Treatment Part)</title>
          <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 16.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6930" spread="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 16 (N=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9710" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C(12h) and C(12h,ss) of Deleobuvir (Combined Treatment Part)</title>
        <description>Concentration of Deleobuvir at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>C(12h) and C(12h,ss) of Deleobuvir (Combined Treatment Part)</title>
          <description>Concentration of Deleobuvir at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C(12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090" spread="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C(12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" spread="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Combined Treatment Part)</title>
        <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Combined Treatment Part)</title>
          <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6080" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38100" spread="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax and Cmax,ss of Deleobuvir (Multiple Rising Dose Part)</title>
        <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 9.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of Deleobuvir (Multiple Rising Dose Part)</title>
          <description>Maximum measured concentration of Deleobuvir on Day 1 and at steady state on Day 9.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2010" spread="41.5"/>
                    <measurement group_id="O2" value="3740" spread="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1380" spread="48.3"/>
                    <measurement group_id="O2" value="3650" spread="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Multiple Rising Dose Part)</title>
        <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 (Multiple Rising Dose Part)</title>
          <description>Area under the concentration-time curve of CD 6168 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1690" spread="56.0"/>
                    <measurement group_id="O2" value="2920" spread="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2810" spread="63.1"/>
                    <measurement group_id="O2" value="6960" spread="106.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax and Cmax,ss of CD 6168 (Multiple Rising Dose Part)</title>
        <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of CD 6168 (Multiple Rising Dose Part)</title>
          <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 9.
CD 6168 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" spread="60.5"/>
                    <measurement group_id="O2" value="516" spread="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451" spread="66.3"/>
                    <measurement group_id="O2" value="1130" spread="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Multiple Rising Dose Part)</title>
        <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Multiple Rising Dose Part)</title>
          <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3940" spread="38.7"/>
                    <measurement group_id="O2" value="6060" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2840" spread="51.7"/>
                    <measurement group_id="O2" value="5270" spread="102.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax and Cmax,ss of BI 208333 (Multiple Rising Dose Part)</title>
        <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of BI 208333 (Multiple Rising Dose Part)</title>
          <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 9.
BI 208333 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766" spread="41.5"/>
                    <measurement group_id="O2" value="1050" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="576" spread="44.4"/>
                    <measurement group_id="O2" value="983" spread="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</title>
        <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</title>
          <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" spread="27.2"/>
                    <measurement group_id="O2" value="342" spread="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 9 (N=6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" spread="42.7"/>
                    <measurement group_id="O2" value="701" spread="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</title>
        <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir on Day 1 and after the last administration on Day 9: at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg Deleobuvir</title>
            <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
          </group>
          <group group_id="O2">
            <title>600 mg Deleobuvir</title>
            <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Multiple Rising Dose Part)</title>
          <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 9.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="36.8"/>
                    <measurement group_id="O2" value="57.9" spread="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="61.3"/>
                    <measurement group_id="O2" value="116.0" spread="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax and Cmax,ss of CD 6168 (Combined Treatment Part)</title>
        <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of CD 6168 (Combined Treatment Part)</title>
          <description>Maximum measured concentration of CD 6168 on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="902" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4860" spread="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C(12h) and C(12h,ss) of CD 6168 (Combined Treatment Part)</title>
        <description>Concentration of CD 6168 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>C(12h) and C(12h,ss) of CD 6168 (Combined Treatment Part)</title>
          <description>Concentration of CD 6168 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C(12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488" spread="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C(12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1650" spread="102.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Combined Treatment Part)</title>
        <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of BI 208333 (Combined Treatment Part)</title>
          <description>Area under the concentration-time curve of BI 208333 over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9130" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13600" spread="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax and Cmax,ss of BI 208333 (Combined Treatment Part)</title>
        <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of BI 208333 (Combined Treatment Part)</title>
          <description>Maximum measured concentration of BI 208333 on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1450" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 16 (N=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2060" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C(12h) and C(12h,ss) of BI 208333 (Combined Treatment Part)</title>
        <description>Concentration of BI 208333 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>C(12h) and C(12h,ss) of BI 208333 (Combined Treatment Part)</title>
          <description>Concentration of BI 208333 at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
BI 208333 is a major metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C(12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520" spread="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C(12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447" spread="101.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
        <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) and AUC(0-12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
          <description>Area under the concentration-time curve of CD 6168 acylglucuronide over the uniform dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511" spread="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3560" spread="120.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
        <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
          <description>Maximum measured concentration of CD 6168 acylglucuronide on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" spread="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 16 (N=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457.0" spread="106.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C(12h) and C(12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
        <description>Concentration of CD 6168 acylglucuronide at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>C(12h) and C(12h,ss) of CD 6168 Acylglucuronide (Combined Treatment Part)</title>
          <description>Concentration of CD 6168 acylglucuronide at the end of the dosing interval 0 to 12 h on Day 1 and at steady state on Day 16.
CD 6168 acylglucuronide is a metabolite of Deleobuvir.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C(12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C(12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.0" spread="122.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24h) and AUC(0-24h,ss) of Faldaprevir (Combined Treatment Part)</title>
        <description>Area under the concentration-time curve of Faldaprevir over the uniform dosing interval 0 to 24 h on Day 1 and at steady state on Day 16.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24h) and AUC(0-24h,ss) of Faldaprevir (Combined Treatment Part)</title>
          <description>Area under the concentration-time curve of Faldaprevir over the uniform dosing interval 0 to 24 h on Day 1 and at steady state on Day 16.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44800" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h,ss) on Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66200" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax and Cmax,ss of Faldaprevir (Combined Treatment Part)</title>
        <description>Maximum measured concentration of Faldaprevir on Day 1 and at steady state on Day 16.</description>
        <time_frame>After the first administration of Deleobuvir+Faldaprevir on Day 1 and after the last administration on Day 16 at 0 (5 min before administration on Day 16), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,12, 24 h after drug administration in the morning.</time_frame>
        <population>PKS including patients with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
            <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax and Cmax,ss of Faldaprevir (Combined Treatment Part)</title>
          <description>Maximum measured concentration of Faldaprevir on Day 1 and at steady state on Day 16.</description>
          <population>PKS including patients with available data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4060.0" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax,ss on Day 16 (N=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5940.0" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration (Day 1) until end of trial examination (15 to 21 days after first administration)</time_frame>
      <desc>Subjects were required to report spontaneously any AEs. In addition, each subject was assessed by the investigator at pre-defined timepoints and whenever it was deemed necessary by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>400 mg Deleobuvir</title>
          <description>400 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. Low dose of multiple rising dose part.</description>
        </group>
        <group group_id="E2">
          <title>600 mg Deleobuvir</title>
          <description>600 mg Deleobuvir administered twice daily for 9 days. Oral administration with 240 mL of water under fed conditions. High dose of multiple rising dose part.</description>
        </group>
        <group group_id="E3">
          <title>600 mg Deleobuvir + 120 mg Faldaprevir</title>
          <description>600 mg Deleobuvir administered twice daily and 120 mg Faldaprevir administered once daily for 16 days.
Oral administration with 240 mL of water under fed conditions. Combined treatment part; conducted after multiple rising dose part.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

